Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ART0380 + Irinotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ART0380 | ART-0380|ART 0380 | ATR Inhibitor 16 | ART0380 inhibits ATR activity leading to decreased phopshorylation of Chk1, which may result in impaired DNA damage repair, induction of apoptosis in tumor cells, and antitumor activity (NCI Drug Dictionary, (Ann Oncol 34 (2023): S475-S476). | |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM negative | Advanced Solid Tumor | predicted - sensitive | ART0380 + Irinotecan | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with the combination of Camptosar (irinotecan) and ART0380 in patients with advanced solid tumors was well tolerated and resulted in an objective response rate of 23% (13/57) overall, 45% (9/20) in ATM negative patients, 22% (4/18) with low ATM expression, and 0% (0/13) with high ATM expression (Cancer Res (2025) 85 (8_Supplement_2): CT267; NCT04657068). | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 + Irinotecan ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |